Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
32.53
+0.72 (2.26%)
Jun 10, 2026, 9:41 AM EDT - Market open
Vera Therapeutics Employees
Vera Therapeutics had 339 employees as of March 31, 2026. The number of employees increased by 90 or 36.14% since the number was last reported on December 31, 2025.
Employees
339
Change
90
Growth
36.14%
Revenue / Employee
n/a
Profits / Employee
-$1,088,357
Market Cap
2.34B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 339 | 90 | 36.14% |
| Dec 31, 2025 | 249 | 137 | 122.32% |
| Dec 31, 2024 | 112 | 61 | 119.61% |
| Dec 31, 2023 | 51 | 5 | 10.87% |
| Dec 31, 2022 | 46 | 29 | 170.59% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Alumis | 227 |
| Immunome | 206 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 154 |
| IDEAYA Biosciences | 145 |
| Pharvaris | 134 |
| Aurinia Pharmaceuticals | 128 |
VERA News
- 4 days ago - Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Vera Therapeutics announces alignment with FDA on earlier ORIGIN 3 eGFR analysis - TheFly
- 7 days ago - Raymond James sees unique buying opportunity in Vera after FDA alignment - TheFly
- 8 days ago - Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy - GlobeNewsWire
- 19 days ago - Vera Therapeutics Transcript: AGM 2026 - Transcripts
- 26 days ago - Vera Therapeutics price target lowered to $91 from $95 at Evercore ISI - TheFly
- 4 weeks ago - Vera Therapeutics reports Q1 EPS ($1.69), consensus ($1.37) - TheFly
- 4 weeks ago - Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire